MX2015006856A - Compuestos imidazopiridina. - Google Patents
Compuestos imidazopiridina.Info
- Publication number
- MX2015006856A MX2015006856A MX2015006856A MX2015006856A MX2015006856A MX 2015006856 A MX2015006856 A MX 2015006856A MX 2015006856 A MX2015006856 A MX 2015006856A MX 2015006856 A MX2015006856 A MX 2015006856A MX 2015006856 A MX2015006856 A MX 2015006856A
- Authority
- MX
- Mexico
- Prior art keywords
- sgc
- group
- imidazo
- prevention
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
Se proporciona una composición farmacéutica para tratar o prevenir enfermedades cardiovasculares, que tienen actividades de sGC sobre la base de la mejora de las señales de cGMP. [Medio para la Solución] Se ha descubierto que compuestos de imidazo[1,2-a]piridina que tienen un grupo carbamoílo en la posición 3 y un grupo cíclico particular en la posición 8 por medio de un grupo metilenoxi, o una sal de este, tienen activación de sGC, y son útiles como ingredientes activos de composiciones farmacéuticas para tratar o prevenir diversas enfermedades cardiovasculares relacionadas con sGC, en particular, enfermedades de las arterias periféricas, claudicación intermitente, isquemia crítica de los miembros inferiores, hipertensión e hipertensión pulmonar, por lo cual se completa la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012262962 | 2012-11-30 | ||
PCT/JP2013/082057 WO2014084312A1 (ja) | 2012-11-30 | 2013-11-28 | イミダゾピリジン化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015006856A true MX2015006856A (es) | 2016-02-17 |
Family
ID=50827943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015006856A MX2015006856A (es) | 2012-11-30 | 2013-11-28 | Compuestos imidazopiridina. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9278968B2 (es) |
EP (1) | EP2927231B1 (es) |
JP (1) | JP6056872B2 (es) |
KR (1) | KR102093608B1 (es) |
CN (1) | CN104822680B (es) |
AU (1) | AU2013353117A1 (es) |
BR (1) | BR112015012571B1 (es) |
CA (1) | CA2891976C (es) |
EA (1) | EA027909B1 (es) |
ES (1) | ES2644611T3 (es) |
HK (1) | HK1212984A1 (es) |
IL (1) | IL238874A0 (es) |
MX (1) | MX2015006856A (es) |
PH (1) | PH12015501102B1 (es) |
PL (1) | PL2927231T3 (es) |
PT (1) | PT2927231T (es) |
TW (1) | TW201439090A (es) |
WO (1) | WO2014084312A1 (es) |
ZA (1) | ZA201503794B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8778964B2 (en) * | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
WO2015140199A1 (de) | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
WO2015165933A2 (de) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | 6-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
JP2017529330A (ja) * | 2014-08-14 | 2017-10-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換キノリン−4−カルボキサミドおよびその使用 |
US10214526B2 (en) * | 2015-02-05 | 2019-02-26 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof |
EP3253758B1 (de) * | 2015-02-05 | 2019-04-03 | Bayer Pharma Aktiengesellschaft | N-substituierte 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamid-derivate als stimulatoren der löslichen guanylatcyclase (sgc) zur behandlung von kardiovaskulären erkrankungen |
EA201792346A1 (ru) | 2015-05-06 | 2018-05-31 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) |
SI3325013T2 (sl) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba |
EP3328382A4 (en) * | 2015-09-17 | 2018-12-19 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
EA201891416A1 (ru) | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
JP7237823B2 (ja) | 2016-10-11 | 2023-03-13 | バイエル ファーマ アクチエンゲゼルシャフト | Sgcアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ |
US10918639B2 (en) | 2016-10-11 | 2021-02-16 | Bayer Pharma Aktiengesellschaft | Combination containing SGC stimulators and mineralocorticoid receptor antagonists |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
US20210177846A1 (en) | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020249117A1 (zh) * | 2019-06-12 | 2020-12-17 | 华东理工大学 | 抗高血压的多元醇化合物及其衍生物 |
CN113046754B (zh) * | 2019-12-28 | 2023-01-03 | 江苏苏博特新材料股份有限公司 | 一种苯并咪唑季铵盐钢筋缓蚀剂及其制备方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0266890A1 (en) * | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
JPH07242666A (ja) * | 1994-03-08 | 1995-09-19 | Fujisawa Pharmaceut Co Ltd | 複素環化合物 |
SE9700661D0 (sv) * | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
AU4543899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
EP1083894A1 (en) * | 1998-06-08 | 2001-03-21 | Advanced Medicine, Inc. | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE |
AU4428899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of cyclooxygenase-2 |
EP1086065A4 (en) * | 1998-06-08 | 2001-03-28 | Advanced Medicine Inc | COMBINATORY SYNTHESIS OF LIBRARIES OF MULTIBINDING SUBSTANCES |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
JP2003513064A (ja) * | 1999-11-05 | 2003-04-08 | ユニバーシティ カレッジ ロンドン | 可溶性グアニル酸シクラーゼのアクチベーター |
KR100830859B1 (ko) * | 2000-04-27 | 2008-05-21 | 아스텔라스세이야쿠 가부시키가이샤 | 이미다조피리딘 유도체 및 이를 함유하는 의약 조성물 |
DE10021069A1 (de) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
CA2311483A1 (en) | 2000-06-12 | 2001-12-12 | Gregory N Beatch | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
US20040048866A1 (en) * | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
DE102006020327A1 (de) | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) * | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102006054757A1 (de) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
PL2547678T3 (pl) * | 2010-03-18 | 2016-10-31 | Związki przeciwzapalne | |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EP2575473B1 (en) * | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2011161099A1 (de) * | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
JP5940062B2 (ja) | 2010-07-09 | 2016-06-29 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 環縮合4−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用 |
EP2682394A1 (de) | 2010-07-09 | 2014-01-08 | Bayer Intellectual Property GmbH | 1H-Pyrazolo[3,4-b]pyridin-Triazine Verbindungen und ihre Verwendung zur Behandlung bzw. Prophylaxe von Herz-Kreislauf-Erkrankungen |
DE102010031667A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung |
DE102010031666A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Carbamat-substituierte Diaminopyrimidine und ihre Verwendung |
DE102010031665A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
US20140171434A1 (en) | 2011-01-11 | 2014-06-19 | Bayer Pharma Aktiengessellschaft | Substituted imidazopyridines and imidazopyridazines and the use thereof |
US8569339B2 (en) * | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
DE102011007272A1 (de) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
WO2012143510A1 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung |
DE102011075398A1 (de) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituierte Imidazopyridazine und ihre Verwendung |
EP2716642B1 (en) * | 2011-05-30 | 2016-07-20 | Astellas Pharma Inc. | Imidazopyridine compound |
RU2014103960A (ru) | 2011-07-06 | 2015-08-20 | Байер Интеллектуэль Проперти Гмбх | Гетероарилзамещенные пиразолопиридины и их применение в качестве стимуляторов растворимой гуанилатциклазы |
AP2014007541A0 (en) | 2011-09-02 | 2014-03-31 | Bayer Ip Gmbh | Substituted annellated pyrimidine and the use thereof |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
-
2013
- 2013-11-28 TW TW102143539A patent/TW201439090A/zh unknown
- 2013-11-28 JP JP2014549894A patent/JP6056872B2/ja active Active
- 2013-11-28 BR BR112015012571-9A patent/BR112015012571B1/pt active IP Right Grant
- 2013-11-28 CN CN201380062525.1A patent/CN104822680B/zh active Active
- 2013-11-28 CA CA2891976A patent/CA2891976C/en active Active
- 2013-11-28 EP EP13858992.4A patent/EP2927231B1/en active Active
- 2013-11-28 KR KR1020157016680A patent/KR102093608B1/ko active IP Right Grant
- 2013-11-28 WO PCT/JP2013/082057 patent/WO2014084312A1/ja active Application Filing
- 2013-11-28 PT PT138589924T patent/PT2927231T/pt unknown
- 2013-11-28 EA EA201591050A patent/EA027909B1/ru not_active IP Right Cessation
- 2013-11-28 ES ES13858992.4T patent/ES2644611T3/es active Active
- 2013-11-28 MX MX2015006856A patent/MX2015006856A/es active IP Right Grant
- 2013-11-28 PL PL13858992T patent/PL2927231T3/pl unknown
- 2013-11-28 US US14/428,798 patent/US9278968B2/en not_active Expired - Fee Related
- 2013-11-28 AU AU2013353117A patent/AU2013353117A1/en not_active Abandoned
-
2015
- 2015-05-18 IL IL238874A patent/IL238874A0/en unknown
- 2015-05-18 PH PH12015501102A patent/PH12015501102B1/en unknown
- 2015-05-27 ZA ZA2015/03794A patent/ZA201503794B/en unknown
-
2016
- 2016-01-29 HK HK16101051.6A patent/HK1212984A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2927231A4 (en) | 2016-04-20 |
WO2014084312A1 (ja) | 2014-06-05 |
ES2644611T3 (es) | 2017-11-29 |
US20150232464A1 (en) | 2015-08-20 |
JP6056872B2 (ja) | 2017-01-11 |
EP2927231B1 (en) | 2017-09-20 |
KR102093608B1 (ko) | 2020-03-26 |
PH12015501102A1 (en) | 2015-07-27 |
CA2891976A1 (en) | 2014-06-05 |
BR112015012571B1 (pt) | 2022-05-24 |
TW201439090A (zh) | 2014-10-16 |
CN104822680B (zh) | 2016-10-12 |
KR20150090157A (ko) | 2015-08-05 |
US9278968B2 (en) | 2016-03-08 |
EA027909B1 (ru) | 2017-09-29 |
HK1212984A1 (zh) | 2016-06-24 |
PL2927231T3 (pl) | 2018-01-31 |
BR112015012571A2 (pt) | 2019-12-17 |
JPWO2014084312A1 (ja) | 2017-01-05 |
ZA201503794B (en) | 2016-11-30 |
PT2927231T (pt) | 2017-10-31 |
EA201591050A1 (ru) | 2016-04-29 |
AU2013353117A1 (en) | 2015-06-04 |
EP2927231A1 (en) | 2015-10-07 |
PH12015501102B1 (en) | 2015-07-27 |
CA2891976C (en) | 2020-07-21 |
IL238874A0 (en) | 2015-07-30 |
CN104822680A (zh) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501102A1 (en) | Imidazopyridine compound | |
MX2013014082A (es) | Compuestos de imidazopiridina. | |
MX2013011854A (es) | Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos. | |
PH12015502839B1 (en) | Antiviral compounds | |
CA2875877C (en) | Syk inhibitors | |
CU20150123A7 (es) | DOS FORMAS CRISTALINAS DEL COMPUESTO( 4,6-DIAMINO-2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO?(3,4-b)PIRIDIN-3-IL)PIRIMIDIN-5-IL)CARBAMATO DE METILO | |
CN103415520B8 (zh) | 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用 | |
GEP201706774B (en) | Heterocyclyl compounds | |
MX2016006336A (es) | Compuestos pirazolopirimidina. | |
WO2012068234A3 (en) | Antiviral compounds | |
GEP20176631B (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
GEP20186838B (en) | 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors | |
MX342309B (es) | Derivados de [1,2,3]traizolo[4,5-d]pirimidina como agonistas del receptor canabinoide 2. | |
AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
MX2014000452A (es) | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). | |
GEP201606540B (en) | New indolizine derivatives, method for their preparation and pharmaceutical compositions containing thereof | |
GEP20135780B (en) | Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents | |
MY173573A (en) | Pyridin-4-yl derivatives | |
MX346248B (es) | Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2. | |
PH12020550956A1 (en) | Sgc stimulators | |
PH12014502465A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists | |
UY33041A (es) | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico | |
MX340574B (es) | Imidazo pirazinas. | |
PH12015502429A1 (en) | Dicarboxylic acid compound | |
MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |